Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Treatment of Dysmenorrhoea With the OVA TENS Apparatus

This study has been completed.
Vitacon AS, Vegamot 8, 7048 Trondheim, Norway
Information provided by:
The Hospital of Vestfold Identifier:
First received: September 22, 2005
Last updated: January 12, 2007
Last verified: January 2007

September 22, 2005
January 12, 2007
September 2005
Not Provided
Change in VAS pain score
Same as current
Complete list of historical versions of study NCT00225836 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Treatment of Dysmenorrhoea With the OVA TENS Apparatus
Treatment of Dysmenorrhoea With the OVA TENS Apparatus

Dysmenorrhoea (menstrual pain) is a common complaint among women, leading to use of analgesics, reduced quality of life, and interference with daily activities such as going to work or school.

Transcutaneous electrical nerve stimulation (TENS) is a well established method for treatment of pain. Several clinical studies have shown TENS treatment to be effective against dysmenorrhoea. A TENS apparatus specifically developed for the treatment of dysmenorrhoea has now become commercially available (OVA), but is has not been tested in clinical studies.

This study will be done to evaluate the clinical utility of treatment with OVA in women with primary dysmenorrhoea.

Study aims: To compare perception of dysmenorrhoea with and without use of OVA.

Design: Prospective, clinical study lasting four months. The women will use the OVA apparatus during every other menstruation.

Inclusion: 20 female volunteers with primary dysmenorrhoea.

Exclusion: Pregnancy, either ongoing or planned during the study period. Secondary dysmenorrhoea.

Consent: The participants will receive verbal and written information and will sign a consent form.

Randomisation: The participants are randomised to start with either active treatment or observation by drawing a closed, opaque envelope containing the forms for registration of perception of pain.

Registering pain: The participants will mark their perceived degree of dysmenorrhoea daily on 10 cm visual analogue scale (VAS) during each menstruation.

Filling in forms: During each of the four menstruations throughout the study period the participants will respond daily to the questions on the form and note degree of pain on the VAS. At the end of each menstruation they will mail the current form in a stamped and addressed envelope to the study coordinator.

Statistics: We assume that a difference of 2 VAS-points is required for an effect to be of clinical interest. One-sided t-test for paired data will be used in the analysis.

Power calculation using the statistics program SSD v7.0 has shown that 16 participants is required to demonstrate a difference of 2 points at level of significance p=0.01, 90% power and assumed standard deviation of 2.

Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Device: OVA (TENS apparatus)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
May 2006
Not Provided

Inclusion Criteria:

  • Primary dysmenorrhoea

Exclusion Criteria:

  • Pregnancy
Child, Adult, Senior
Contact information is only displayed when the study is recruiting subjects
OVA study
Not Provided
Not Provided
Not Provided
Not Provided
The Hospital of Vestfold
Vitacon AS, Vegamot 8, 7048 Trondheim, Norway
Principal Investigator: Hjalmar A Schiotz, MD, PhD Consultant Gynecologist, The Hospital of Vestfold, Tonsberg, Norway
The Hospital of Vestfold
January 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP